The story of Sildenafil offers a complicated case study for analysts eyeing drug companies. While first sales were explosive, current patent expiration and the rise of alternative versions have severely impacted https://heidiiskw164831.aboutyoublog.com/52344431/the-blue-pill-and-the-pharmaceutical-industry-a-risky-stake